• TH
    • EN
    • Register
    • Login
    • Forgot Password
    • Help
    • Contact
  • Register
  • Login
  • Forgot Password
  • Help
  • Contact
  • EN 
    • TH
    • EN
View Item 
  •   Home
  • สถาบันวิจัยระบบสาธารณสุข (สวรส.) - Health Systems Research Institute (HSRI)
  • Research Reports
  • View Item
  •   Home
  • สถาบันวิจัยระบบสาธารณสุข (สวรส.) - Health Systems Research Institute (HSRI)
  • Research Reports
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A Study of Adverse Events and Unsafety After Receiving Covid-19 Vaccine of Chronically Ill Patients and Elderly : Case Study of Ramathibodi Hospital, Bangkok, Thailand

พูลสุข เจนพานิชย์ วิสุทธิพันธ์; Poolsuk Janepanish Visudtibhan; แสงทอง ธีระทองคำ; Sangthong Terathongkum; จิราพร ไลนิงเกอร์; Jiraporn Lininger; วนาพรรณ ชื่นอิ่ม; Wanaphan Chuen-im; พลอยแก้ว จารุวร; Ploykaew Jaruworn; สุนันท์ วงศ์วิศวะกร; Sunun Wongvisavakorn;
Date: 2565-12
Abstract
This cross-sectional research study aimed to study adverse events and unsafety after receiving types of Covid-19 vaccine. The sample of the study was people with sevem groups of chronic illnesses and older adults who received the Covid-19 vaccine from Ramathiodi Hospital, Bangkok. Purposive sampling was 1,254 cases. Data were collected by face-to-face interview, telephone, or online using the personal questionnaire and the Adverse Events questionnaire. Results showed that almost half of the participants received AstraZeneca+AstraZeneca of 48.79 %. Participants with chronic illnesses and older adults who received the different types of Covid-19 vaccine had the significant difference of adverse events both first dose (χ2=20.21, p<0.001), second dose (χ2=47.7, p<0.001), and the two-dose crossover vaccine (χ2=50.3, p<0.001). The participants who received the two-dose crossover vaccine of Astrazeneca+Pfizer/Moderna had the most adverse events of 67.7%. However, the two-dose from the same group vaccine of Sinovac/Sinopharm+Sinovac/Sinopharm reported only 28% of adverse events. People who were younger than 60 years old with chronic disease had a statistically significant difference in the greatest adverse events compared to healthy older adults with chronic disease who received both the first and second doses of the Covid-19 vaccine (χ2=24.36, p<0.001; χ2=18.31, p<0.001). In addition, Pfizer/Moderna reported the greatest adverse events of 17.4-38.7% such as local symptoms (pain, swelling, redness, hotness, itchy at the injection site), fever, and muscle pain. Moreover, twenty-two participants reported severe adverse events and need to receive first aid and visit the doctor. The results of this study suggested continuing the policy recommendations for vaccination by using the same type of vaccine Sinovac/Sinopharm or AstraZeneca. Using the cross-over type of vaccine is not recommended, especially, in-group of people who were less than 60 years old and had chronic illnesses to decrease adverse events and increase safety.
Copyright ผลงานวิชาการเหล่านี้เป็นลิขสิทธิ์ของสถาบันวิจัยระบบสาธารณสุข หากมีการนำไปใช้อ้างอิง โปรดอ้างถึงสถาบันวิจัยระบบสาธารณสุข ในฐานะเจ้าของลิขสิทธิ์ตามพระราชบัญญัติสงวนลิขสิทธิ์สำหรับการนำงานวิจัยไปใช้ประโยชน์ในเชิงพาณิชย์
Fulltext
Icon
Name: hs2922.pdf
Size: 1.410Mb
Format: PDF
Download

Report broken link | User Manual
(* In case of download problems)

Total downloads:
Today: 0
This month: 1
This budget year: 12
This year: 11
All: 12
 

 
 


 
 
Show full item record
Collections
  • Research Reports [2182]

    งานวิจัย


DSpace software copyright © 2002-2016  DuraSpace
Privacy Policy | Contact Us | Send Feedback | Report Problem
Theme by 
Atmire NV
 

 

Browse

HSRI Knowledge BankDashboardCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjectsSubjectsการบริการสุขภาพ (Health Service Delivery) [526]กำลังคนด้านสุขภาพ (Health Workforce) [85]ระบบสารสนเทศด้านสุขภาพ (Health Information Systems) [270]ผลิตภัณฑ์ วัคซีน และเทคโนโลยีทางการแพทย์ (Medical Products, Vaccines and Technologies) [87]ระบบการเงินการคลังด้านสุขภาพ (Health Systems Financing) [129]ภาวะผู้นำและการอภิบาล (Leadership and Governance) [1092]ปัจจัยสังคมกำหนดสุขภาพ (Social Determinants of Health: SDH) [207]วิจัยระบบสุขภาพ (Health System Research) [28]ระบบวิจัยสุขภาพ (Health Research System) [19]

DSpace software copyright © 2002-2016  DuraSpace
Privacy Policy | Contact Us | Send Feedback | Report Problem
Theme by 
Atmire NV